Gentel Prepares to Launch APiX Platform, Assays in H1 as It Looks to Build Services Arm

Gentel believes its APiX assays and platform will be attractive to both its core pharma customers, who are interested in adding new assays to compound screening programs, and to new academic customers, who might be attracted to the system's lower cost.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.